Cipla Health strengthens its play in beauty and personal care
CHL is strengthening its play in the fast-growing beauty and personal care sector
CHL is strengthening its play in the fast-growing beauty and personal care sector
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
KRKA holds 51% and Laurus Labs holds 49% shareholding
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Total value of the supplies of FC will be US$ 2.773 million
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly
Subscribe To Our Newsletter & Stay Updated